S. Dirnhofer, Basel (Switzerland), et al.
Authors Conclusion from the abstract: Based on data from this prospective clinical trial on FL, we identified tumor microenvironmental characteristics which may allow prognostic stratification with respect to immuno‐ and combined immuno‐ and immunomodulatory therapy. Our analysis implicates that lenalidomide might help to overcome the adverse prognostic implication of higher amounts of regulatory T cells in the microenvironment of follicular lymphoma and that it may have particularly favorable effects in cases with higher amounts of TH2‐equivalents as demonstrated by GATA3‐positive T‐cells. Additional analysis by gene expression profiling of the microenvironment may further contribute to a better understanding of this so far still underestimated component of follicular lymphoma.
P. Perez Galan, Barcelona (Spain), et al.
Authors Conclusion from the abstract: In summary, these results support the role of M2 macrophages in FL pathogenesis and suggest that therapies manipulating FL‐M2 crosstalk may be a new strategy, especially in combination with anti‐B cell therapies.
C.L. Batlevi, New York, NY (USA), et al.
M. Federico, Modena (Italy), et al.
Authors Conclusion from the abstract: In patients with intermediate‐high risk FL according to FLIPI2 and requiring systemic therapy, omission of R‐maintenance resulted in a significantly lower 3‐year PFS, despite the attainment of a post‐induction complete metabolic response.
F. Morschhauser, Lille (France), et al.
Authors Conclusion from the abstract: Tazemetostat 800 mg BID appears to be generally well tolerated with observed meaningful clinical activity and durability of response in pts with R/R FL. ORR was pronounced in pts with EZH2 activating mutations. Late onset responses have been reported on tazemetostat. Given the consistently favorable safety and low rates of discontinuation due to TEAEs, these encouraging phase 2 data demonstrate that EZH2 inhibition may be an important and effective therapeutic target in FL.